# AIM ImmunoTech Inc. (AIM)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $744,401.942  
**Price:** $0.46 (+4.52%)

> AIM ImmunoTech Inc. is a biopharmaceutical company specializing in immunology-focused drug development. The company concentrates on researching and developing therapeutics for multiple types of cancers, viral diseases, immune disorders, and immune-deficiency conditions, addressing areas where existing treatment options are limited or inadequate. AIM ImmunoTech’s work centers on modulating the immune system, with a particular emphasis on leveraging innate immune pathways.

Its lead product, Ampligen (rintatolimod), is a double-stranded RNA immunomodulator being developed for use in oncology, viral infections, and immune-related disorders. Another key product, Alferon N Injection (interferon alfa), is a purified, natural-source alpha interferon indicated for certain viral conditions. AIM ImmunoTech operates primarily in the healthcare and biotechnology sector in the United States and collaborates with clinical and academic partners to advance its programs. Founded in 1966 and headquartered in Ocala, Florida, the company plays a niche role in the immuno-pharma segment by focusing on immune-based therapeutic approaches.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $88,000 | — | -$12M | -$14M | — |
| 2024 | $170,000 | — | -$20M | -$17M | — |
| 2023 | $202,000 | — | -$32M | -$29M | — |
| 2022 | $141,000 | — | -$20M | -$19M | — |
| 2021 | $135,000 | — | -$19M | -$19M | — |
| 2020 | $163,000 | — | -$15M | -$14M | — |
| 2019 | $140,000 | — | -$12M | -$9M | — |
| 2018 | $367,000 | — | -$11M | -$10M | — |
| 2017 | $437,000 | — | -$11M | -$8M | — |
| 2016 | $92,000 | — | -$14M | -$8M | — |
| 2015 | $133,000 | — | -$17M | -$15M | — |
| 2014 | $197,000 | -$1M | -$19M | -$17M | — |
| 2013 | $150,000 | -$1M | -$17M | -$16M | — |
| 2012 | $213,000 | -$2M | -$20M | — | — |
| 2011 | $161,000 | -$882,000 | -$14M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $6M | $16M | -$10M | $3M | $4M |
| 2024 | $9M | $10M | -$1M | $2M | $3M |
| 2023 | $19M | $9M | $10M | $5M | — |
| 2022 | $40M | $2M | $38M | $27M | — |
| 2021 | $58M | — | $57M | $32M | — |
| 2020 | $65M | — | $61M | $39M | $2M |
| 2019 | $21M | — | $13M | $1M | $2M |
| 2018 | $14M | — | $6M | $299,000 | $3M |
| 2017 | $14M | — | $9M | $1M | — |
| 2016 | $19M | — | $15M | $2M | — |
| 2015 | $23M | — | $20M | $2M | — |
| 2014 | $29M | $4M | $25M | $2M | — |
| 2013 | $32M | $3M | $29M | $803,000 | — |
| 2012 | $58M | $13M | $45M | $2M | — |
| 2011 | $44M | $6M | $38M | $3M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$11M | — | — |
| 2024 | -$15M | $18,000 | -$15M |
| 2023 | -$21M | — | — |
| 2022 | -$16M | $86,000 | -$16M |
| 2021 | -$14M | $41,000 | -$14M |
| 2020 | -$10M | $22,000 | -$10M |
| 2019 | -$9M | $68,000 | -$9M |
| 2018 | -$11M | $51,000 | -$11M |
| 2017 | -$8M | $20,000 | -$8M |
| 2016 | -$7M | $160,000 | -$8M |
| 2015 | -$16M | $240,000 | -$16M |
| 2014 | -$14M | $504,000 | -$14M |
| 2013 | -$17M | $898,000 | -$18M |
| 2012 | -$13M | $6M | -$19M |
| 2011 | -$10M | $2M | -$12M |

Source: [CompaniesByCap](https://companiesbycap.com/company/AIM)